FDA Advisory Panel To Review Cell Therapeutics' Pixantrone

February 8, 2010 10:29 AM |

The Food and Drug Administration will select an advisory panel to review Cell Therapeutics Inc.'s (Nasdaq: CTIC) lymphoma treatment pixantrone due to safety concerns. The stock price plummeted 34 cents to 72 cents.

Tags:

Search

About this Entry

This page contains a single entry by published on February 8, 2010 10:29 AM.

Earnings Surge For Hasbro was the previous entry in this blog.

Seanergy Terminates Purchase Of Vessel is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12